Sphingosine pathway modulating compounds for the treatment of cancers
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
1. A method for treating a cancer or myeloproliferative disorder in a mammalian subject, comprising the step of:
administering to a mammalian subject in need of treatment for a cancer or myeloproliferative disorder an effective amount of ozanimod or a pharmaceutically acceptable salt thereof,
wherein the cancer or myeloproliferative disorder is hepatocellular carcinoma (HCC).
2. The method of claim 1 , wherein the mammalian subject is a human.
3. The method of claim 1 , wherein the administering step comprises administering the hydrochloride salt of ozanimod to the mammalian subject.
4. The method of claim 2 , wherein the administering step comprises administering the hydrochloride salt of ozanimod to the mammalian subject.